SRI cancer researcher gets “distinct” praise

Dr. Bob Kerbel, a senior scientist in biological sciences and the Odette Cancer Research Program, was named a 2011 Man of Distinction by the Israel Cancer Research Fund. The award, which recognizes people who exhibit "leadership, innovation and excellence within their communities and beyond," was presented to Kerbel on October 12, 2011 at the Fourth Annual Men of Distinction Awards in Toronto.

Kerbel, who is the Canada Research Chair in Tumour Biology, Angiogenesis and Antiangiogenic Therapy, was honoured for his cutting-edge research on metronomic chemotherapy and antiangiogenic drugs, both of which aim to make cancer treatments safer and more effective. His discoveries are being tested in clinical trials, particularly in breast, ovarian, colorectal and pediatric cancers.

Dr. Kerbel was honoured by ICRF alongside two other men of distinction, Peter Freed and Geoffrey Matus, who are Canadian entrepreneurs.

The mission of the Israel Cancer Research Fund is to gather Israel's science and research talent to cure the disease. In addition to hosting the annual Men of Distinction Awards, the organization has contributed to over 1,850 research grants.

Download Nexus Autumn 2011 (PDF, 7.8 mb)